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This phase II study was designed to evaluate the activity and safety of a combination of irinotecan, docetaxel and oxaliplatin in
metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Forty patients with measurable distant metastasis received
irinotecan 150mgm
 2 and docetaxel 60mgm
 2 on day 1, and oxaliplatin 85mgm
 2 on day 2. Cycles were repeated every 3 weeks.
The primary end point was to demonstrate a 50% improvement in time-to-progression (TTP) over historical controls. All patients
were evaluable. Median TTP was 6.5 months (95% confidence interval (CI) 5.6–7.4), the overall response rate was 50% (95% CI 35–
65%) and the median overall survival was 11.5 months (95% CI 8.7–14.3). Grade 3/4 neutropaenia occurred in 47.5% of patients.
There were four episodes of febrile neutropaenia in three patients. Other non-haematological grade 3 toxicities included diarrhoea in
four patients (10%), vomiting in three patients (7.5%) and mucositis in two patients (5%). The irinotecan, docetaxel and oxaliplatin
combination chemotherapy is an active and well-tolerated novel regimen for treating metastatic gastric or GEJ adenocarcinoma and
deserves further evaluation in randomised trials and in combination with molecular targeting agents.
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Gastric cancer is still one of the most prevalent human
malignancies, and remains the second leading cause of cancer
mortality in the world (Kamangar et al, 2006). While the incidence
of distal tumours is declining in the Western countries, the
incidence of gastroesophageal junction (GEJ) adenocarcinomas,
which appear to be more virulent, is rapidly increasing (Devesa
and Fraumeni, 1999). The outcome among patients with gastric
cancer is determined by the stage of the disease at presentation.
Generally, a potentially curative resection is possible in only 30%
of all recently diagnosed patients (Hundahl et al, 2000), since in
the majority of cases the disease is locally advanced or metastatic.
Systemic chemotherapy is often used in these patients because
randomised trials have shown that combination regimens confer
a survival advantage and an improvement in quality-of-life when
compared with supportive care alone. Overall, the results have
been mostly unsatisfactory with a median time-to-progression
(TTP) of 4 months and a median overall survival (OS) of 8–9
months (Wagner et al, 2006).
During the last few years, several new drugs including irinotecan
(Bleiberg, 1999; Kohne et al, 1999), oxaliplatin (Louvet et al, 2002;
Al-Batran et al, 2004), capecitabine (Ajani, 2006) and docetaxel
(Thuss-Patience et al, 2006) have been demonstrated to be active
in metastatic gastric cancer. The incorporation of these agents in
new combinations has resulted in regimens such as DCF
(docetaxel, cisplatin, fluorouracil), EOX (epirubicin, oxaliplatin,
capecitabine) and ILF (irinotecan, leucovorin, fluorouracil), which
could have a role in the treatment of these patients but survival is
still very poor (Rivera et al, 2007). Recently, the combination of
irinotecan and oxaliplatin showed activity in advanced gastric
cancer with a 50% response rate (RR) and a favourable toxicity
profile in 32 patients (Souglakos et al, 2004). Furthermore, a
synergic effect has been reported with the combination of
docetaxel and irinotecan both in untreated and treated patients
with gastric cancer (Chang et al, 2003; Hawkins et al, 2003). It
seemed thus appropriate to test the activity and toxicity of three
new agents in combination, namely irinotecan, docetaxel and
oxaliplatin (IDO), in patients with metastatic gastric or GEJ cancer.
These agents have distinct and complementary mechanisms of
action, they lack cross-resistance, and they have favourable toxicity
profiles. To this purpose, we first performed a phase I study of
this combination according to the modified Fibonacci schema. Six
patients entered this study, and the recommended phase II doses
were as follows: irinotecan 150mgm
 2 and docetaxel 60mgm
 2
on day 1, oxaliplatin 85mgm
 2 on day 2, with cycles repeated
every 3 weeks.
PATIENTS AND METHODS
Patient selection
Patients with gastric or GEJ adenocarcinoma with distant
metastasis not previously treated by systemic chemotherapy were
enrolled onto the study. Adjuvant chemotherapy without agents
under the study was allowed if completed at least 6 months before.
The patients were required to have measurable disease, ECOG
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sperformance status p2, life expectancy 43 months, age between
18 and 75 years, adequate bone marrow (absolute neutrophil count
X1500ml
 1, platelet count X100000ml
 1), renal (serum creatinine
p1.5mgdl
 1) and liver (serum bilirubin p1.5mgdl
 1) functions,
normal cardiac function, absence of second primary tumour other
than non-melanoma skin cancer or in situ cervical carcinoma,
no CNS involvement, no previous radiotherapy in parameter
lesions, no concurrent uncontrolled medical illness. The protocol
was approved and carried out according to the principles of the
Declaration of Helsinki and Good Clinical Practice Guidelines,
and all patients gave their written informed consent to participate
onto the trial.
Treatment
Treatment consisted of irinotecan 150mgm
 2 diluted in 250ml of
normal saline as a 1h infusion followed by docetaxel 60mgm
 2
diluted in 500ml of normal saline as 1h infusion on day 1, and
oxaliplatin 85mgm
 2 diluted in 500ml 5% dextrose as a 2h
infusion on day 2. Cycles were repeated every 3 weeks. Antiemetic
treatment consisted of an antiserotonin agent plus dexamethasone
in a 15min infusion before starting chemotherapy. In addition,
orally prednisone premedication was used for prophylaxis of
docetaxel-induced hypersensitivity and fluid retention. Atropine
0.25mg subcutaneously was administered for prophylaxis of
cholinergic syndrome. Granulocyte colony-stimulating factor
(G-CSF) was used only as secondary prophylaxis once patients
had febrile neutropaenia or documented neutropaenic infection.
Treatment was postponed by a maximum of 2 weeks if the
absolute neutrophil count was less than 1500ml
 1 or the platelet
count was less than 100000ml
 1. The dose of irinotecan was
reduced by 20% of the previous dose in case of grade X3
diarrhoea, whereas oxaliplatin was reduced by 25% in case of
grade X2 peripheral neuropathy, and docetaxel by 25% in case
of the following toxicities: grade X3 neutropaenia lasting
more than 7 days (or in presence of fever), second incidence
of febrile neutropaenia despite G-CSF support administered
after the first occurrence, grade X3 diarrhoea and grade X3
stomatitis.
Chemotherapy was generally administered on an outpatient
basis for a maximum of eight cycles and was discontinued in case
of unacceptable toxicity, treatment delay longer than 2 weeks,
disease progression or patients’ refusal.
Pretreatment and follow-up studies
Pretreatment evaluation included clinical history and physical
examination, automated blood cell count, biochemical profile, ECG
and computed tomography of thorax and abdomen. Endoscopy
was performed only in case of complete remission of all
measurable lesions. Blood counts were obtained weekly; biochem-
ical profile was repeated every 3 weeks. All measurable parameters
of disease were re-evaluated every 6 weeks, until the tumour
progressed.
Evaluation of response and toxicity
Patients were evaluated for response to chemotherapy every two
cycles of treatment. Responses were assessed by at least two
observers, and were confirmed by an expert independent
radiologist. The RECIST criteria were used to evaluate clinical
response (Therasse et al, 2000), and all objective responses were
confirmed by CT scans at least 4 weeks after the initial
documentation of response. Time-to-progression and OS were
calculated from the date of first chemotherapy cycle to the date of
disease progression, death or last follow-up evaluation, respec-
tively. Toxicity was assessed in each treatment cycle using the
National Cancer Institute Common Toxicity Criteria (version 3.0).
Statistical considerations
The primary end point of this study was to test the hypothesis that
TTP will improve by 50%. The major secondary end point was RR.
Other secondary end points were OS and safety. The study was
designed to have an 80% power to show an improvement in
median TTP from 4 to 6 months with a 5% type I error, two sides,
assuming exponential progression-free survival times. A sample
size of 40 patients was required to meet these requirements
(A’Hern, 2001). Time-to-progression and OS were analysed
according to the Kaplan–Meier method, and were updated to 30
April 2007.
RESULTS
Patients’ characteristics
From February 2004 to April 2006, 40 patients with metastatic
gastric or GEJ cancer entered onto this multicentre study. All
patients were evaluable for efficacy and toxicity. The pretreat-
ment characteristics of patients are listed in Table 1. None of the
patients had previously received chemotherapy for advanced
disease; six patients had received adjuvant chemotherapy
without irinotecan, docetaxel or oxaliplatin several months
before they entered this study (median, 14 months; range, 9–23
months).
Efficacy
Median TTP was 6.5 months (95% confidence interval (CI) 5.6–
7.4) (Figure 1). Only six patients progressed within the first 2
months, whereas at the time of this analysis all but one patient
progressed. Among 40 assessable patients, we observed two (5%)
complete responses (CRs) and 18 (45%) partial responses (PRs),
for an overall RR of 50% (95% CI 35–65%). Disease remained
stable in 14 (35%) patients (Table 2). Responses according to
predominant site of disease, were as follows: liver 16 of 28 patients
(57%); nodes/peritoneum 3 of 10 patients (30%); lung 1 of 2
patients. RRs did not significantly differ according to number of
metastatic sites: one site, 7 of 12 patients (58%); two sites, 9 of 18
patients (50%); and three or more sites, 4 of 10 patients (40%).
Responses were seen in 3 of 6 patients (50%) who received
adjuvant chemotherapy and in 17 of 34 patients (50%) not
previously treated with chemotherapy. Responses were observed
also in 13 of 26 patients (50%) with primary tumour not resected
and in 7 of 14 patients (50%) with primary tumour resected.
Response rates and TTP did not differ when patients were
evaluated according to the primary site of disease (gastric: 50%
and 6.5 months; GEJ: 50% and 6.3 months, respectively). Upon
disease progression, 21 patients (52.5%) received a second-line
chemotherapy, including epirubicin/fluorouracil (n¼16) and
cisplatin/capecitabine (n¼5). Median OS was 11.5 months (95%
CI 8.7–14.3 months) (Figure 2). One- and two-year survivals were
42 and 15.8%, respectively. Thirty-eight patients had died at the
time of the present evaluation. Twenty-three of the 32 patients
(72%) who had tumour-related symptoms before therapy showed
an improvement in at least one of their symptoms without
worsening of any other symptom.
Toxicity
Haematological toxicity data are listed in Table 3. A total of 242
cycles of IDO regimen were analysed in 40 patients, with a median
of seven cycles administered per patient (range, 1–8 cycles). The
most important toxicity was myelosuppression, which occurred
almost always on day 8 (docetaxel nadir). Grade 3 and 4
neutropaenia were recorded in 40 and in 7.5% of the patients,
respectively. Four episodes of febrile neutropaenia occurred in 3
Irinotecan, docetaxel and oxaliplatin for gastric cancer
L Di Lauro et al
594
British Journal of Cancer (2007) 97(5), 593–597 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s(7.5%) patients. In these patients, a 25% dose reduction of
docetaxel was required, whereas treatment was postponed in two
(5%) patients and in six (2.5%) cycles because of a delay in bone
marrow recovery. Mean irinotecan, docetaxel and oxaliplatin
dose intensities were 45.45, 18.36 and 27.17mgm
 2 per week,
respectively, which are equivalent at 90.9, 91.8 and 95.9% of the
planned dose intensities for these drugs. Grade 3 thrombocyto-
paenia was observed in 2.5% of the patients, and grade 3 anaemia
occurred in 10% of the patients.
Non-haematological toxicities are listed in Table 4. Mild-to-
moderate diarrhoea, which was reversible and manageable in all
cases, occurred in 40% of the patients, while grade 3 diarrhoea
developed in four (10%) patients. Alopecia was frequent. Mild
nausea and vomiting was encountered in 45% of the patients, and
was severe in three (7.5%) patients. Mild and transient peripheral
neurotoxicity was recorded in 35% of the patients. Hypersensiti-
vity reactions, which not precluded chemotherapy continuation,
were recorded in 5% of the patients. No cardiotoxicity or
treatment-related deaths were observed.
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Figure 1 Median TTP for all patients.
Table 2 Objective response in 40 patients
Response No. of patients %
Complete response 2 5
Partial response 18 45
Stable disease 14 35
Progressive disease 6 15
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Figure 2 Overall survival for all patients.
Table 1 Patient’s characteristics
Characteristic No. of patients %
Patients evaluable 40 100
Age (years)
Median 62
Range 38–75
Sex
Male 28 70
Female 12 30
ECOG PS
08 2 0
12 6 6 5
26 1 5
Disease location
Gastric 30 75
GEJ 10 25
Histologic type
Diffuse 18 45
Intestinal 16 40
Unspecified 6 15
Previous adjuvant chemotherapy 6 15
Status of primary tumour
Unresected 26 65
Resected 14 35
Predominat site of disease
Liver 28 70
Nodes/peritoneum 10 25
Lung 2 5
No. of metastatic sites
11 2 3 0
21 8 4 5
X31 0 2 5
Symptoms
Weight loss
No 13 32.5
p10% 16 40
410% 11 27.5
Anorexia
No 21 52.5
Yes 19 47.5
Dysphagia
No 23 57.5
Yes 17 42.5
Pain
No 20 50
Yes 20 50
Abbreviations: ECOG PS¼Eastern Cooperative Oncology Group Performance
Status; GEJ¼gastroesophageal junction.
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sDISCUSSION
Classical cisplatin-based regimens obtain responses in 20–40% of
the patients with metastatic gastric or GEJ cancer, a median TTP of
about 4 months and a median survival of 8–9 months (Wagner
et al, 2006). Despite recent advances in the chemotherapy of this
disease, the survival advantage appears to be marginal, and no
regimens have emerged that could be considered standard.
To develop a potentially more effective front-line chemotherapy,
combination regimens have generally included one or two of the
three new drugs active in gastric cancer, namely irinotecan,
docetaxel and oxaliplatin. This is the first study that combines
these three agents.
The IDO regimen appears to be an active treatment in
previously untreated patients with metastatic gastric cancer, since
the primary end point of this study was largely achieved with a
median TTP of 6.5 months. Noteworthy are also the overall RR of
50% and the median survival of 11.5 months. These data appear of
particular importance considering that liver involvement and
primary tumour unresected were recorded in 70 and 65% of the
patients, respectively.
These results compare favourably with those reported in several
trials using new generation treatment regimens. In a recent phase
III randomised trial, the combination of docetaxel, cisplatin and
fluorouracil demonstrated significant superiority in comparison to
the reference regimen of cisplatin and fluorouracil (CF). Never-
theless, TTP, OS and RR were 5.6 months, 9.2 months and 37%,
respectively (Van Cutsem et al, 2006). In another phase III study of
337 patients with advanced gastric cancer, irinotecan in combina-
tion with bolus fluorouracil and infused fluorouracil over 22h did
not result in statistically significant improvement in TTP (5.0 vs 4.2
months) or OS (9.0 vs 8.7 months) compared with CF, but showed
a better safety profile (Dank et al, 2005). Moreover, our results are
similar to those observed with the combination of EOX in the
REAL-2 phase III study. In this trial, the EOX regimen showed RR
of 48% and OS of 11.2 months in 239 patients with advanced
oesophageal, EGJ or gastric carcinoma with a manageable toxicity
(Cunningham et al, 2006).
The combination used in the current study compares favourably
also with regimens including two of these three new agents. In
two phase II studies in advanced gastric cancer, combined
irinotecan and oxaliplatin yielded a median TTP of 5.5 and 5.3
months, and an OS of 8.5 and 9.5 months (Souglakos et al, 2004;
Woell et al, 2006). When irinotecan was used in combination
with docetaxel in 90 untreated patients with advanced gastric
cancer enrolled in two phase II studies, a median TTP of 3.8 and
4.5 months with an OS of 8.2 and 9.0 months were observed
(Hawkins et al, 2003; Park et al, 2006). Treatment results do
not seem to improve by combining oxaliplatin and docetaxel, since
TTP and OS were 4.4 and 9.5 months, respectively, in 71 patients
with stage IV gastroesophageal and/or stomach cancer (Richards
et al, 2006).
Of considerable importance in patients with metastatic gastric
cancer are treatment tolerance and quality-of-life, since these
patients have generally symptoms at baseline. The IDO regimen
demonstrated a tolerable toxicity profile in the present trial. The
most important side effect was grade 3–4 neutropaenia, which
occurred in less than 50% of the patients, and almost always at
docetaxel nadir. Grade 3 diarrhoea was observed in four patients
(10%). Other severe toxic effects were infrequent, as were dose
reductions and treatment delays. Although quality-of-life was not
measured in our study, the majority of patients enjoyed a clear
clinical benefit during treatment, as evidenced by the relief of pain
and other tumour-related symptoms. Treatment compliance was
good, as demonstrated by relative dose intensities of 90.9% for
irinotecan, 91.8% for docetaxel and 95.8% for oxaliplatin. More-
over, chemotherapy was generally administered on an outpatient
basis.
In conclusion, we found that the combination of irinotecan,
docetaxel and oxaliplatin is active with an acceptable safety profile
in the first-line treatment of metastatic gastric or GEJ adenocarci-
noma, and should be compared with other active regimens (e.g.
ECF and EOX) in a randomised fashion. However, in order to
further improve treatment results in this disease, the addition of
targeted therapy to cytotoxic agents should be considered. In two
recent phase II trials, the combination of irinotecan, cisplatin and
bevacizumab (Shah et al, 2006), and cetuximab combined with
FOLFIRI (Pinto et al, 2007), both produced encouraging results
with TTP and OS remarkably improved over historical controls. In
this context, the IDO regimen, with its activity and safety profile,
could be a good candidate to enhance survival in metastatic gastric
or GEJ cancer patients.
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